Gross Profit Trends Compared: Takeda Pharmaceutical Company Limited vs Biogen Inc.

Takeda's Profit Soars, Biogen Faces Decline

__timestampBiogen Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 201485322880001256834000000
Thursday, January 1, 201595234000001271973000000
Friday, January 1, 201699701000001173296000000
Sunday, January 1, 2017106439000001274610000000
Monday, January 1, 2018116366000001437534000000
Tuesday, January 1, 2019124225000002201424000000
Wednesday, January 1, 2020116394000002203504000000
Friday, January 1, 202188720000002462160000000
Saturday, January 1, 202278951000002783406000000
Sunday, January 1, 202373022000002832257000000
Monday, January 1, 202496759000002832257000000
Loading chart...

Igniting the spark of knowledge

Gross Profit Trends: Takeda vs. Biogen

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the gross profit trajectories of Takeda Pharmaceutical Company Limited and Biogen Inc. from 2014 to 2023. Takeda, a Japanese giant, consistently outperformed Biogen, with its gross profit peaking at approximately 2.83 trillion in 2023, marking a 125% increase from 2014. In contrast, Biogen, a leading American biotech firm, saw its gross profit decline by about 15% over the same period, ending at around 7.3 billion in 2023. Notably, Takeda's significant leap in 2019, coinciding with its acquisition of Shire, underscores its strategic growth. Meanwhile, Biogen's fluctuating profits reflect challenges in its product pipeline. This comparison highlights the contrasting financial strategies and market dynamics faced by these pharmaceutical leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025